Geovax Stock Quote: Financial Insights and Updates

As of the latest data, Geovax's stock price has seen a significant fluctuation, ranging from $0.55 to $1.20 per share over the past year.

This volatility can be attributed to the company's ongoing research and development efforts in the field of infectious disease vaccines.

Geovax has consistently demonstrated a strong revenue growth, with a 25% increase in sales from 2020 to 2021.

The company's financial stability is further supported by a low debt-to-equity ratio of 0.23, indicating a manageable level of debt.

GeoVax Labs Inc's financial information can be a bit complex, but let's break it down simply. The company's revenue is estimated to be around $14 million in 2025, $6 million in 2026, $305 million in 2027, and $367 million in 2028.

One thing to note is that the company has reported a net loss in the past, with a net profit of -$15 million in 2025 and -$21 million in 2026. However, by 2027, the company is expected to turn a profit, with a net profit of $202 million.

Here's a summary of the company's revenue estimates for the next few years:

The company's market capitalization is around $18.3 million, and it's listed on the NASDAQ exchange.

The revenue estimates for GeoVax Labs are quite varied, ranging from $3 to $14 in the next few years.

In 2025, the average revenue estimate from 4 analysts is $3 USD, while in 2026, it's also $3 USD from 3 analysts.

The average revenue estimate for 2027 is $14 USD from 5 analysts, and in 2028, it's $6 USD from 3 analysts.

The average earnings per share (EPS) estimate for 2025 is -0.768 USD from 5 analysts, while in 2026, it's -0.467 USD from 3 analysts.

In 2027, the average EPS estimate is -0.460 USD from 3 analysts, and in 2028, it's -1.162 USD from 5 analysts.

Here's a summary of the average revenue and EPS estimates for the next few years:

Keep in mind that these estimates are based on the opinions of analysts and may not reflect the actual performance of the company.

GeoVax Labs Inc. raised approximately $8.5 million in an offering priced above the market.

This significant funding will help the clinical-stage biotechnology company develop its immunotherapies and vaccines against cancer and infectious diseases. The company's stock price, however, took a hit, sliding 20% in premarket trade.

The company's financials were a major factor in the stock's decline, with a net loss of $15 million in 2025, according to GeoVax's estimates. This loss was largely due to the company's significant research and development expenses, which totaled $24 million in 2025.

GeoVax's financials were a major focus in 2025, with the company's revenue estimates ranging from $14 million to $367 million over the next four years. The company's average revenue estimate for 2025 is $14 million, based on analyst estimates.

Here's a breakdown of GeoVax's estimated revenue and net loss for the next four years:

GeoVax Labs has a history of releasing earnings reports, with the most recent actual EPS being -0.910 USD for Q3 2024. These reports are typically released on specific dates, such as 11/12/2024 for Q3 2024.

The company has also held annual general meetings, with the most recent one resulting in an actual EPS of -12.450 USD on 08/01/2023. GeoVax Labs also participates in conferences, such as the 3rd Annual ROTH Healthcare Opportunities Conference, which they attended in August and September 2024.

Here's a list of upcoming earnings reports, based on the company's calendar:

Company events are a crucial part of any business's calendar, and GeoVax Labs is no exception. GeoVax Labs has a few notable events coming up.

Their Q4 2024 Earnings Report is estimated to be around -0.768 USD and will be released on 03/26/2025. This will be an important milestone for the company.

Here's a rundown of their upcoming earnings reports:

GeoVax Labs has had a significant number of earnings reports in the past few years. The company's actual EPS (Earnings Per Share) has been mostly negative.

One notable trend is that the company's EPS has decreased over time, with some exceptions. For example, in Q2 2022, the EPS was -2.700 USD, but in Q3 2023, it was -3.300 USD.

A list of GeoVax Labs' earnings reports shows the actual EPS for each quarter. Here's a breakdown of the EPS for each quarter in the past few years:

The company has also held two annual general meetings, one in 2023 and one in 2022, with EPS of -12.450 USD and -45.600 USD, respectively.

GeoVax Labs, Inc. is participating in the 3rd Annual ROTH Healthcare Opportunities Conference.

The conference will take place in Atlanta, Georgia, with the exact date not specified.

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases.

The company is listed on the Nasdaq stock exchange under the ticker symbol GOVX.

GeoVax Labs, Inc. is a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases.

The company's participation in the conference was announced through a Globe News Wire release.